PGI16 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.765
https://www.valueinhealthjournal.com/article/S1098-3015(12)02478-3/fulltext
Title :
PGI16 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02478-3&doi=10.1016/j.jval.2012.08.765
First page :
A328
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
276